Hoxb4 upregulation by Xuan Bi Tong Yu Fang confers cardioprotection via repression of the Wnt/β-catenin pathway in myocardial ischemia-reperfusion injury - Report - MDSpire
Advertisement
Hoxb4 upregulation by Xuan Bi Tong Yu Fang confers cardioprotection via repression of the Wnt/β-catenin pathway in myocardial ischemia-reperfusion injury
Clinical Report: Upregulation of Hoxb4 by Xuan Bi Tong Yu Fang Provides Cardioprotection
Overview
Xuan Bi Tong Yu Fang (XBTYF) demonstrates cardioprotective effects in myocardial ischemia-reperfusion injury (MIRI) by enhancing Hoxb4 expression and inhibiting the Wnt/β-catenin pathway. This study provides insights into the therapeutic mechanisms of XBTYF, highlighting its potential as an adjunctive treatment for MIRI.
Background
Myocardial ischemia-reperfusion injury (MIRI) is a significant complication in cardiovascular disease management, leading to substantial myocardial damage. Current therapeutic strategies often fall short, necessitating the exploration of alternative treatments. Traditional Chinese medicine, particularly XBTYF, offers promising avenues for mitigating MIRI through multi-target mechanisms.
Data Highlights
Group
CK Levels
AST Levels
cTnI Levels
Myocardial Infarction Area
Sham
Low
Low
Low
Minimal
Model
High
High
High
Large
XBTYF (High Dose)
Decreased
Decreased
Decreased
Reduced
Positive Control
Moderate
Moderate
Moderate
Moderate
Key Findings
XBTYF significantly reduced myocardial enzyme levels in MIRI models.
Histopathological analysis showed improved myocardial architecture and reduced fibrosis with XBTYF treatment.
RNA sequencing identified Hoxb4 as a key gene upregulated by XBTYF.
XBTYF inhibited the Wnt/β-catenin signaling pathway, correlating with decreased apoptosis.
Ginsenoside Rg3 exhibited strong binding affinity to Hoxb4, suggesting a mechanism of action.
Clinical Implications
The findings suggest that XBTYF could be considered as a complementary therapy for patients experiencing myocardial ischemia-reperfusion injury. Clinicians may explore the integration of traditional Chinese medicine into standard care protocols to enhance myocardial protection during reperfusion.
Conclusion
XBTYF offers a novel approach to mitigating myocardial ischemia-reperfusion injury through the modulation of Hoxb4 and the Wnt/β-catenin pathway. Further research is warranted to validate its clinical efficacy and potential integration into therapeutic strategies.
